Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AIkido Pharma Inc. stock logo
AIKI
AIkido Pharma
$2.13
-2.7%
$2.69
$3.31
$11.48
$11.68M0.9379,326 shs143,877 shs
Grande Group Limited stock logo
GRAN
Grande Group
$1.17
-8.2%
$1.40
$0.80
$5.91
$31.40MN/A4,017 shs9,089 shs
MDB Capital Holdings, LLC stock logo
MDBH
MDB Capital
$2.90
-1.9%
$3.15
$2.45
$4.80
$30.39M1.22,307 shs6,902 shs
Plutus Financial Group Limited stock logo
PLUT
Plutus Financial Group
$2.68
+4.9%
$2.79
$1.88
$4.19
$39.14M1.64114 shs56 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AIkido Pharma Inc. stock logo
AIKI
AIkido Pharma
-1.79%-14.45%-15.12%-32.82%-63.50%
Grande Group Limited stock logo
GRAN
Grande Group
+12.09%-3.08%-5.91%+26.37%-70.64%
MDB Capital Holdings, LLC stock logo
MDBH
MDB Capital
0.00%+1.72%-3.28%-4.10%-14.96%
Plutus Financial Group Limited stock logo
PLUT
Plutus Financial Group
+6.52%+3.85%+3.81%-13.34%-8.02%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AIkido Pharma Inc. stock logo
AIKI
AIkido Pharma
$2.13
-2.7%
$2.69
$3.31
$11.48
$11.68M0.9379,326 shs143,877 shs
Grande Group Limited stock logo
GRAN
Grande Group
$1.17
-8.2%
$1.40
$0.80
$5.91
$31.40MN/A4,017 shs9,089 shs
MDB Capital Holdings, LLC stock logo
MDBH
MDB Capital
$2.90
-1.9%
$3.15
$2.45
$4.80
$30.39M1.22,307 shs6,902 shs
Plutus Financial Group Limited stock logo
PLUT
Plutus Financial Group
$2.68
+4.9%
$2.79
$1.88
$4.19
$39.14M1.64114 shs56 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AIkido Pharma Inc. stock logo
AIKI
AIkido Pharma
-1.79%-14.45%-15.12%-32.82%-63.50%
Grande Group Limited stock logo
GRAN
Grande Group
+12.09%-3.08%-5.91%+26.37%-70.64%
MDB Capital Holdings, LLC stock logo
MDBH
MDB Capital
0.00%+1.72%-3.28%-4.10%-14.96%
Plutus Financial Group Limited stock logo
PLUT
Plutus Financial Group
+6.52%+3.85%+3.81%-13.34%-8.02%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AIkido Pharma Inc. stock logo
AIKI
AIkido Pharma
0.00
N/AN/AN/A
Grande Group Limited stock logo
GRAN
Grande Group
1.00
SellN/AN/A
MDB Capital Holdings, LLC stock logo
MDBH
MDB Capital
1.00
SellN/AN/A
Plutus Financial Group Limited stock logo
PLUT
Plutus Financial Group
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest AIKI, PLUT, GRAN, and MDBH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/31/2026
Grande Group Limited stock logo
GRAN
Grande Group
UpgradeSell (D-)Sell (D)
8/18/2026
MDB Capital Holdings, LLC stock logo
MDBH
MDB Capital
DowngradeSell (D-)Sell (E+)
8/17/2026
Grande Group Limited stock logo
GRAN
Grande Group
DowngradeSell (D)Sell (D-)
8/14/2026
Plutus Financial Group Limited stock logo
PLUT
Plutus Financial Group
Reiterated RatingSell (E+)
8/3/2026
Grande Group Limited stock logo
GRAN
Grande Group
UpgradeSell (D-)Sell (D)
7/2/2026
MDB Capital Holdings, LLC stock logo
MDBH
MDB Capital
Reiterated RatingSell (D-)
6/29/2026
Grande Group Limited stock logo
GRAN
Grande Group
Reiterated RatingSell (D-)
(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AIkido Pharma Inc. stock logo
AIKI
AIkido Pharma
N/AN/AN/AN/A$19.27 per shareN/A
Grande Group Limited stock logo
GRAN
Grande Group
$1.81M15.91N/AN/A$0.30 per share3.90
MDB Capital Holdings, LLC stock logo
MDBH
MDB Capital
$4.91M6.07N/AN/A$4.81 per share0.60
Plutus Financial Group Limited stock logo
PLUT
Plutus Financial Group
$1.34M30.64N/AN/A$0.73 per share3.66
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AIkido Pharma Inc. stock logo
AIKI
AIkido Pharma
-$7.17M-$3.88N/AN/AN/AN/A-18.21%-16.94%N/A
Grande Group Limited stock logo
GRAN
Grande Group
-$3.47MN/AN/AN/AN/AN/AN/AN/AN/A
MDB Capital Holdings, LLC stock logo
MDBH
MDB Capital
-$21.25M-$2.18N/AN/AN/AN/A-39.77%-38.48%N/A
Plutus Financial Group Limited stock logo
PLUT
Plutus Financial Group
-$5.06MN/AN/AN/AN/AN/AN/AN/AN/A

Latest AIKI, PLUT, GRAN, and MDBH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/31/2026Q4 2026
Grande Group Limited stock logo
GRAN
Grande Group
N/A-$0.04N/A-$0.04N/A$0.76 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AIkido Pharma Inc. stock logo
AIKI
AIkido Pharma
N/AN/AN/AN/AN/A
Grande Group Limited stock logo
GRAN
Grande Group
N/AN/AN/AN/AN/A
MDB Capital Holdings, LLC stock logo
MDBH
MDB Capital
N/AN/AN/AN/AN/A
Plutus Financial Group Limited stock logo
PLUT
Plutus Financial Group
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AIkido Pharma Inc. stock logo
AIKI
AIkido Pharma
N/A
29.54
29.54
Grande Group Limited stock logo
GRAN
Grande Group
0.03
0.54
0.54
MDB Capital Holdings, LLC stock logo
MDBH
MDB Capital
N/A
39.85
39.85
Plutus Financial Group Limited stock logo
PLUT
Plutus Financial Group
N/A
3.45
3.45

Institutional Ownership

CompanyInstitutional Ownership
AIkido Pharma Inc. stock logo
AIKI
AIkido Pharma
10.88%
Grande Group Limited stock logo
GRAN
Grande Group
N/A
MDB Capital Holdings, LLC stock logo
MDBH
MDB Capital
0.35%
Plutus Financial Group Limited stock logo
PLUT
Plutus Financial Group
N/A

Insider Ownership

CompanyInsider Ownership
AIkido Pharma Inc. stock logo
AIKI
AIkido Pharma
8.60%
Grande Group Limited stock logo
GRAN
Grande Group
N/A
MDB Capital Holdings, LLC stock logo
MDBH
MDB Capital
55.83%
Plutus Financial Group Limited stock logo
PLUT
Plutus Financial Group
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
AIkido Pharma Inc. stock logo
AIKI
AIkido Pharma
45.49 million5.01 millionNot Optionable
Grande Group Limited stock logo
GRAN
Grande Group
2024.62 millionN/AN/A
MDB Capital Holdings, LLC stock logo
MDBH
MDB Capital
4010.30 million4.55 millionNot Optionable
Plutus Financial Group Limited stock logo
PLUT
Plutus Financial Group
1015.35 millionN/AN/A

Media Sentiment Over Time

Top Headlines

View All Headlines
AIkido Pharma stock logo

AIkido Pharma NASDAQ:AIKI

$2.13 -0.06 (-2.74%)
As of 09/3/2026

AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is headquartered in New York, New York.

Grande Group stock logo

Grande Group NASDAQ:GRAN

$1.17 -0.11 (-8.24%)
As of 03:56 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Headquartered in Hong Kong, we are a holding company incorporated in the British Virgin Islands, and all of our business is carried out by our wholly-owned Operating Subsidiary in Hong Kong, Grande Capital. Grande Capital is a boutique financial firm that focuses on providing quality corporate finance advisory services to clients in Asia. Grande Capital is a licensed corporation under the SFO to engage in Type 1 (dealing in securities) and Type 6 (advising on corporate finance) regulated activities in Hong Kong. According to the Industry Report, Grande Capital ranked 10th out of a total of 301 licensed corporations licensed to carry out Type 6 regulated activity, in terms of number of deals for financial advisers in Hong Kong from March 31, 2023 to March 31, 2024, with a market share of 3.6%. Since Grande Capital, our Operating Subsidiary, first obtained its licenses under the SFO on January 23, 2018, Grande Capital has sponsored and completed 16 successful IPOs (i.e. IPO that successfully closed and listed) on the HKSE. For the six months ended September 20, 2024 and the years ended March 31, 2023 and 2024, Grande Capital sponsored and completed nil, 3 and 3 successful IPOs on the HKSE, respectively. Furthermore, for the years ended March 31, 2023 and 2024 and the six months ended September 30, 2024, 2, nil and 1 listing applicants mandated Grande Capital as their listing sponsors for their IPO processes on the HKSE, respectively. From September 30, 2024 to the date of the prospectus, Grande Capital has not received any new listing sponsorship mandate. The service offerings of our Operating Subsidiary mainly include the following: (1) IPO sponsorship and related services Grande Capital acts as sponsor to companies aspiring to list on the HKSE. Grande Capital takes the principal role of advising and guiding listing applicants throughout the IPO process, coordinating the listing progress, conducting due diligence, performing all duties of a sponsor as required under the applicable rules and regulations and acting as the primary channel of communication with the regulators such as the HKSE and the HKSFC concerning the listing, in return for a sponsor’s fee. The clients pay us by way of progress payment based on achievement of certain milestones, such as signing of the engagement letter, submission of listing application, and first dealing of shares, in the IPO progress and we recognize the listing sponsorship services fee as our revenue when the performance obligation is satisfied. Since 2022, as part of our IPO sponsorship services, the Operating Subsidiary has also started participating in underwriting syndicates for those IPOs in which the Operating Subsidiary acted as sponsors, in return for underwriting commissions. (2) Corporate financial advisory services Grande Capital also provides a wide range of corporate financial advisory services to clients, which can be broadly classified into the following 3 categories: General advisory services: these mainly include (i) advisory works for private companies, public companies listed on HKSE, as well as their shareholders, advising them on the terms and structures of proposed transactions, such as takeovers, merger and acquisitions, and investment, and the relevant implications of the Hong Kong regulatory framework, which primarily include the HK Listing Rules and the HK Takeovers Codes, in relation to the transactions; and (ii) project coordination works for clients pursuing listing on other stock exchanges, such as U.S. exchanges. The Operating Subsidiary charges a fixed fee payable by progress payment based on achievement of certain milestones, such as submission to the regulators, receiving approvals from the regulators and/or publishing the relevant documents on the HKSE. Independent financial advisory services: these mainly include providing advice to the independent board committee members and independent shareholders of companies listed on HKSE, rendering recommendation and opinions, in return for a fixed fee paid by progress payment based on achievement of certain milestones, such as submission to the regulators, receiving approvals from the regulators and/or publishing the relevant documents on the HKSE. Compliance advisory services: these mainly include advisory works to listed companies in Hong Kong in relation to post-listing compliance matters, in return for a monthly fee. (3) Referral services Since mid-2024, Grande Capital also provide referral services to other professional parties, such as financial institutions, for equity and debt fund raising exercises, for referral fees. Occasionally we may on a case by case basis come across fund-raising exercises which require the introduction of other professional parties in which we may obtain referral fees. Such referral fee is generally based on a percentage of the fee charged by our clients in the particular fund-raising exercises. Grande Capital has been an active player in the equity capital market in Hong Kong, serving clients from a wide spectrum of industry sectors, either listed or planning to list in Hong Kong. Our client base spans Hong Kong, Singapore and the PRC. For the year ended March 31, 2024, we had 16, 6 and 4 clients from Hong Kong, the PRC and Singapore, respectively, while for the year ended March 31, 2023, we had 9, 2 and 5 clients from Hong Kong, the PRC and Singapore, respectively. For the six months ended September 30, 2024, we had 12, 6 and 4 clients from Hong Kong, the PRC and Singapore, respectively. For the nine months ended December 31, 2024, we had 16, 6 and 4 clients from Hong Kong, Mainland China, and Singapore, respectively. Revenues derived from clients in Hong Kong, the PRC and Singapore was approximately 59.2%, 34.0% and 6.8% of our total revenue for the year ended March 31, 2024, respectively, and 34.0%, 50.8% and 15.2% of our total revenue for the year ended March 31, 2023, respectively. Revenues derived from clients in Hong Kong, the PRC and Singapore was approximately 52.9%, 28.9% and 18.2% of our total revenue for the six months ended September 30, 2024, respectively. The sales and marketing function of Grande Capital is primarily performed by our management and project execution team who are responsible for maintaining relationships with existing clients, exploring sales lead from new clients, and maintaining relationships with professional parties partners in the financial services industry. Grande Capital’s projects generally originate from the networks of our management and our project execution team, referrals from existing clients or other professional parties and direct approaches by clients due to our market reputation. Grande Capital maintains a company website which showcases our completed projects. Attributable mainly to the increase of successful IPOs where Grande Capital acted as a sponsor, our revenue increased from approximately US$3.9 million for the year ended March 31, 2023 to approximately US$4.5 million for the year ended March 31, 2024; while our profit before tax increased from approximately US$1.5 million to approximately US$2.1 million in the corresponding years. According to Migo, Hong Kong is one of the world’s largest securities markets by market capitalization. According to the HKSE, there were a total of 2,283 companies and 326 companies listed on the Main Board and GEM in 2023, respectively, with a CAGR of approximately 4.4% and 5.3% since 2014, respectively. Driven by (i) Hong Kong having well-established financial and legal systems with a comprehensive regulatory regime; (ii) Hong Kong’s capital market having a high level of openness to and freedom of capital flow; (iii) financial technology being adopted comprehensively in the financial industry; and (iv) the HKSE opening up new capital sources such as listing exchange traded fund tracking stocks in the Middle East, it is expected that the Hong Kong corporate finance market will continue to grow. Our principal executive offices are located in Admiralty, Hong Kong.

MDB Capital stock logo

MDB Capital NASDAQ:MDBH

$2.90 -0.06 (-1.86%)
As of 03:51 PM Eastern
This is a fair market value price provided by Massive. Learn more.

MDB Capital Holdings, LLC, through its subsidiaries, primarily operates as a broker-dealer. The company operates through two segments, Broker Dealer & Intellectual Property Service, and Technology Development. The Broker Dealer & Intellectual Property Service segment operates as a full-service broker dealer that focuses on conducting private and public securities offerings, as well as providing research services for investment banking due diligence. The Technology Development segment engages in the synthetic biology technology development business. The company was founded in 1997 and is based in Addison, Texas.

Plutus Financial Group stock logo

Plutus Financial Group NASDAQ:PLUT

$2.68 +0.13 (+4.90%)
As of 12:21 PM Eastern
This is a fair market value price provided by Massive. Learn more.

The Mission of Plutus Group “Integrity, Persistence, Professionalism, Innovation and Vitality” are the five core values of Plutus Group. The Company takes “Integrity” as the foundation of our business, “Persistence” as everything customer-oriented, and it provide customers with “Professional” products and quality services. The Company’s business strategy is to practice “Innovation” and “Vigor” in service to its customers. The Company has a development vision is to become a leading Asian financial institution. The Company believes that its greatest responsibility is to create common good with society. The Company will continue to use its influence on financial markets to create a new paradigm. Plutus Group provides financial services through its primary Hong Kong operating subsidiaries, Plutus Securities and Plutus Asset Management. Plutus Securities is licensed with the SFC to carry out Type 1 (dealing in securities) regulated activities and mainly offers (i) securities dealings and brokerage services; (ii) margin financing services; and (iii) underwriting and placing services and is also an exchange participant of the HKEx. Plutus Asset Management is licensed with the SFC to carry out Type 4 (advising on securities) and Type 9 (asset management) regulated activities in Hong Kong and mainly offers (i) asset management services and (ii) investment advisory services to our customers. Our team is familiar with the local and global financial markets and has extensive experience in investment and asset management. Through comprehensive training and our dedication to quality services, our team provides customers with comprehensive professional analysis and investment advice. The principal executive offices of the Company are located at 8/F, 80 Gloucester Road, Wan Chai, Hong Kong. The Company’s registered office in the Cayman Islands is currently located at the office of Quality Corporate Services Ltd., Suite 102, Cannon Place, P.O. Box 712, North Sound Rd., George Town, Grand Cayman, KY1-9006 Cayman Islands, which may be changed from time to time at the discretion of directors. The Company’s agent for service of process in the United States is The Crone Law Group P.C., 500 Fifth Ave, Suite 938, New York, NY.